Archive for the ‘china retractions’ Category
Acta Radiologica has pulled a 2012 article on breast cancer imaging for being a duplicate publication — a sin the retraction notice takes great pains to point out.
As we’ve pointed out before, economics and business journals have few retractions compared with the other academic literature. Opinions vary on why this is, but the fact that only a few journals have plagiarism policies can’t help.
Research Papers in Economics, or RePEc, an organization that maintains a database of economics papers, however, thoroughly investigates accusations of misconduct. A RePEc report, which indicated that the plagiarists were polite enough to cite the original paper, was used in the notice as evidence for a retraction in Economic Modelling.
A few weeks after the paper was published on June 9, comments on PubPeer began accumulating. Commenters called out both potentially manipulated and repeated images. The exact timeline is not clear, because Oncogene does not list a date on the retraction notice, but by August 29 the paper had been retracted.
Here’s the notice for “IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer,” by researchers at Shanghai Jiaotong University School of Medicine and Ruijin Hospital, both in Shanghai, China, and the University of Michigan: Read the rest of this entry »
Here’s the notice for “Microstructural Brain Abnormalities of Children of Idiopathic Generalized Epilepsy With Generalized Tonic-Clonic Seizure: A Voxel-Based Diffusional Kurtosis Imaging Study”: Read the rest of this entry »
The paper, titled “Further Pieces of Evidence to the Pulmonary Origin of Sevoflurane Escaping to the Operating Room During General Anaesthesia,” appeared in Cell Biochemistry and Biophysics and came from a group at various institutions in Harbin, China.
The paper, “Process Evaluation of a Positive Youth Development Program in Hong Kong Based on Different Cohorts,” appeared in 2012 in The Scientific World Journal, and was written by a pair of researchers with appointments in Hong Kong, Macau, Shanghai, and the United States. It has been cited twice, according to Thomson Scientific’s Web of Knowledge.
Another retraction has appeared up for frequent fliers Jun Li, Kailun Zhang and Jiahong Xia at Huazhong Science and Technology University in Wuhan, China.
We’ve covered them twice before, for a variety of retractions, corrections, and expressions of concern.
The retraction, in Clinical and Experimental Immunology, upgrades an expression of concern published earlier this year, and is the team’s fourth.
The title of this post isn’t exactly how the one-sided conversation between the editors of Neuropsychiatric Disease and Treatment and a group of researchers went. But it seems likely it was pretty close.
The paper, “Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells,” appeared in the July 2013 issue of the Journal of Drug Design, Development and Therapy, a Dove Press title.